Showing 901-910 of 20873 results for "".
- EHA 2024: Monoclonal Antibodies Continue to Dominate Multiple Myeloma Treatmentshttps://reachmd.com/news/eha-2024-monoclonal-antibodies-continue-to-dominate-multiple-myeloma-treatments/2467248/Many significant Phase I-III studies targeting haematological malignancies, such as multiple myeloma (MM), were presented at the European Hematology Association Hybrid Congress 2024 (EHA 2024), which took place from 13 – 16 June. MM is the third most prevalent blood cancer w
- Dermavant Publishes ADORING 1 & ADORING 2 Phase 3 Trial Results for Vtama Cream for ADhttps://reachmd.com/news/dermavant-publishes-adoring-1-adoring-2-phase-3-trial-results-vtama-cream-ad/2463173/Dermavant Sciences announced that the data from ADORING 1 and ADORING 2 phase 3 trials of Vtama (tapinarof) cream 1% for adults and children 2 years of age and older with atopic dermatitis (AD) has been published in the Journal of the American Academy of Dermatology. Vtama cream i
- COVID-19 Vaccine Can Help People with Heart Failure Live Longerhttps://reachmd.com/news/covid-19-vaccine-can-help-people-with-heart-failure-live-longer/2463034/Heart failure patients who are vaccinated against COVID-19 have an 82% greater likelihood of living longer than those who are not vaccinated, according to research presented today at Heart Failure 2024, a scientific congress of the European Society of Cardiology (ESC).1 Heart Failure i
- Common Environmental Carcinogens Reduce Lifespan Joyhttps://reachmd.com/news/common-environmental-carcinogens-reduce-lifespan-joy/2462550/Osaka, Japan – If improving your outlook on life really was as simple as "don't worry, be happy," then keeping your spirits up would be a piece of cake. Unfortunately, it's not so simple, as a multitude of factors beyond our control can affect our mood.In a study published i
- Akouos Reports Positive Data from Gene Therapy Trial for Hearing Losshttps://reachmd.com/news/akouos-reports-positive-data-from-gene-therapy-trial-for-hearing-loss/2456956/Elil Lilly and Company subsidiary Akouos has reported encouraging initial data from the Phase I/II AK-OTOF-101 clinical trial of its investigational gene therapy, AK-OTOF, for genetic hearing loss. The trial has demonstrated pharmacologic hearing restoration within 30 days of administrati
- Vaccine Demonstrates Benefit in Delaying Cancer Relapsehttps://reachmd.com/news/vaccine-demonstrates-benefit-in-delaying-cancer-relapse/2456841/Vaccine demonstrates benefit in delaying cancer relapseData from the Phase I trial showed that the cancer vaccine offered an 86 percent reduction in the risk of relapse or death in pancreatic and colorectal cancers.A lymph node-targeted cancer vaccine has
- Telephonic Care Coordination In High-Need, High-Cost Patientshttps://reachmd.com/news/telephonic-care-coordination-in-high-need-high-cost-patients/2487375/Key Takeaways No significant difference was seen in the prespecified coprimary outcomes over 12 months. The same overall pattern was seen in the diabetes subsample and in instrumental variable analyses. Interpretation was limited by low uptake
- Continuous Glucose Monitoring Reduces Glucose Dynamics to 3 Featureshttps://reachmd.com/news/continuous-glucose-monitoring-reduces-glucose-dynamics-to-three-features/2486934/Key Takeaways Three CGM-derived features captured most interindividual variation in glucose dynamics among adults without diagnosed diabetes. The three-feature representation reproduced standardized postprandial glucose trajectories with high accuracy
- Metformin And Glaucoma: Cohort, Meta-Analysis, And Mendelian Randomizationhttps://reachmd.com/news/metformin-and-glaucoma-cohort-meta-analysis-and-mendelian-randomization/2486647/A recent study reports that metformin use was associated with a possible lower glaucoma risk across three complementary analyses in people with diabetes. The study package included a prospective cohort analysis in 24,206
- Retinal Vein Occlusion in Europe: New Data Links the Condition to Long-Term Mortality Riskhttps://reachmd.com/news/retinal-vein-occlusion-in-europe-new-data-links-the-condition-to-long-term-mortality-risk/2483508/Retinal vein occlusion (RVO) is widely known as a leading cause of visual impairment, second only to diabetic retinopathy among retinal vascular diseases. But new findings from the Gutenberg